Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yunnan Baiyao Group Co.,Ltd (000538.SZ)
CNY50.80
+0.75 (+1.50%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 3686, Yunnan Baiyao Street 650500
Kunming, CN
Kunming, CN
CEO
Ming Dong
Website
yunnanbaiyao.com.cn
IPO
1993-12-15
ISIN CNE0000008X7
Description
Operating globally and domestically within China, Yunnan Baiyao Group Co., Ltd. specializes in the pharmaceutical industry. Its diverse portfolio encompasses health supplements, a wide array of medications, medical devices, traditional Chinese medicine ingredients, and even tea. These offerings are marketed under various brand identities, including Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong. The company, established in 1902, maintains its principal offices in Kunming, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY50.80
+0.75 (+1.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
9M
Beta
0.17
Float Shares
1.77B
Free Float %
99.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.08% | -1.60% | -5.41% | -8.37% | -9.27% | -8.79% | -9.27% | -10.32% | -31.30% | +17.13% | +1,507.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
50.80
DCF (Unlevered)
89.24
+75.7%
DCF (Levered)
112.51
+121.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | -2 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.89
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+2.9% Q1'26: +7.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+8.7% Q1'26: +5.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.0% Q1'26: +6.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.2% Q1'26: +18.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+14.5% ★ Q1'26: +24.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.1% ★ Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.08× ★ Q1'26: 0.24× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 12 Rev. Ana. 2 EPS Ana. |
Dec 2028 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.74B
est: 21.62B (-4.1%)
|
22.41B
est: 22.75B (-1.5%)
|
24.31B
est: 24.92B (-2.4%)
|
27.02B
est: 26.70B (+1.2%)
|
29.66B
est: 29.24B (+1.4%)
|
32.74B
est: 33.30B (-1.7%)
|
36.37B
est: 38.46B (-5.4%)
|
36.49B
est: 37.20B (-1.9%)
|
39.11B
est: 39.99B (-2.2%)
|
40.03B
est: 40.64B (-1.5%)
|
41.19B
est: 42.17B (-2.3%)
|
42.54B
42.41B – 42.85B
+0.9% YoY
|
44.10B
43.09B – 46.03B
+3.7% YoY
|
45.66B
45.06B – 46.85B
+3.5% YoY
|
| EBITDA |
3.13B
est: 2.49B (+25.5%)
|
3.33B
est: 2.62B (+27.2%)
|
3.41B
est: 2.87B (+18.7%)
|
4.40B
est: 3.08B (+42.9%)
|
2.98B
est: 3.37B (-11.5%)
|
4.03B
est: 3.84B (+5.0%)
|
4.40B
est: 4.43B (-0.6%)
|
4.16B
est: 4.29B (-3.0%)
|
3.83B
est: 4.61B (-17.0%)
|
4.81B
est: 4.64B (+3.8%)
|
4.84B
est: 4.81B (+0.6%)
|
4.85B
4.84B – 4.89B
+0.9% YoY
|
5.03B
4.92B – 5.25B
+3.7% YoY
|
5.21B
5.14B – 5.35B
+3.5% YoY
|
| EBIT |
3.00B
est: 2.35B (+28.0%)
|
3.22B
est: 2.47B (+30.3%)
|
3.28B
est: 2.70B (+21.2%)
|
4.25B
est: 2.90B (+46.8%)
|
2.82B
est: 3.17B (-11.1%)
|
3.86B
est: 3.61B (+6.9%)
|
4.14B
est: 4.17B (-0.8%)
|
3.81B
est: 4.04B (-5.6%)
|
3.59B
est: 4.34B (-17.4%)
|
4.59B
est: 4.36B (+5.3%)
|
4.61B
est: 4.53B (+1.8%)
|
4.56B
4.55B – 4.60B
+0.9% YoY
|
4.73B
4.62B – 4.94B
+3.7% YoY
|
4.90B
4.84B – 5.03B
+3.5% YoY
|
| Net Income |
2.77B
est: 3.53B (-21.4%)
|
2.92B
est: 3.69B (-20.9%)
|
3.14B
est: 3.95B (-20.4%)
|
3.49B
est: 4.12B (-15.1%)
|
4.18B
est: 4.28B (-2.2%)
|
5.52B
est: 4.95B (+11.4%)
|
2.80B
est: 3.87B (-27.5%)
|
3.00B
est: 3.43B (-12.4%)
|
4.09B
est: 4.67B (-12.3%)
|
4.75B
est: 4.56B (+4.3%)
|
5.15B
est: 5.25B (-1.8%)
|
5.64B
5.54B – 5.83B
+7.5% YoY
|
6.11B
6.04B – 6.18B
+8.3% YoY
|
6.58B
6.46B – 6.80B
+7.6% YoY
|
| SGA |
3.10B
est: 3.09B (+0.4%)
|
3.24B
est: 3.25B (-0.3%)
|
3.94B
est: 3.56B (+10.5%)
|
4.33B
est: 3.82B (+13.5%)
|
5.04B
est: 4.18B (+20.4%)
|
4.57B
est: 4.76B (-4.0%)
|
4.96B
est: 5.50B (-9.8%)
|
4.99B
est: 5.32B (-6.3%)
|
6.04B
est: 5.72B (+5.7%)
|
5.91B
est: 5.99B (-1.2%)
|
6.63B
est: 6.21B (+6.8%)
|
6.26B
6.25B – 6.31B
+0.9% YoY
|
6.50B
6.35B – 6.78B
+3.7% YoY
|
6.73B
6.64B – 6.90B
+3.5% YoY
|
| EPS |
1.90
est: 1.98 (-3.8%)
|
2.00
est: 2.07 (-3.2%)
|
2.16
est: 2.21 (-2.3%)
|
1.96
est: 2.31 (-15.0%)
|
2.34
est: 2.40 (-2.4%)
|
3.09
est: 2.77 (+11.4%)
|
1.58
est: 2.17 (-27.1%)
|
1.90
est: 1.92 (-1.0%)
|
2.29
est: 2.61 (-12.4%)
|
2.66
est: 2.55 (+4.1%)
|
2.89
est: 2.94 (-1.8%)
|
3.16
3.11 – 3.27
+7.5% YoY
|
3.43
3.39 – 3.46
+8.3% YoY
|
3.69
3.62 – 3.81
+7.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
4.72B
OE per share TTM
2.64
Owner's Yield
5.04%
Maintenance CapEx ratio
3.03%
Maint CapEx / Avg PPE
9.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 140 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 2.21% | 1.76M | 0.79% |
| 2 | HSBC MSCI China A UCITS ETF HMCT.L | 0.26% | 353.8K | 0.30% |
| 3 | JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L | 0.25% | 57.1K | 0.40% |
| 4 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.18% | 254.7K | 0.35% |
| 5 | Xtrackers Harvest CSI 300 China A-Shares ETF ASHR | 0.18% | 2.37M | 0.65% |
| 6 | Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L | 0.17% | 542.4K | 0.65% |
| 7 | iShares MSCI China A UCITS ETF CNYE.MI | 0.17% | 171.8K | 0.45% |
| 8 | iShares MSCI China A UCITS ETF CNYA.L | 0.17% | 5.21M | 0.40% |
| 9 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.17% | 228.3K | 0.35% |
| 10 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.16% | 25.5K | 0.65% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
496.8K
Shares Outstanding
1.78B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hongshen Li | Senior Vice President | — | male |
| Jia Ma | Chief Financial Officer | — | male |
| Jing Li | Chief Quality & Process Officer | — | male |
| Jing Xu | Accounting Supervisor | — | — |
| Ming Dong | Vice Chairman & President | — | male |
| Sheng Li Li | Senior Vice President | — | male |
| Shi Chen | Senior Vice President | — | male |
| Tao He | Senior Vice President | — | male |
| Yinghui Qian | Secretary | — | male |
| Zhang Ning | Chief Scientist | — | male |
| Zhao Yun Zhu | Strategic Scientist of Chinese Medicine | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000538.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
